Latest Financials News

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.

M3 Mining Limited has abandoned its energy sector acquisition plans, selling its M3 Energy subsidiary to Jerboa Energy Ltd and recommitting to its core mineral exploration projects.

Antilles Gold’s joint venture has inked key offtake agreements for all gold and copper/gold concentrates from the Nueva Sabana mine, boosting project financing prospects.

Dateline Resources reports promising geochemical anomalies at its Colosseum Gold-REE Project in California, hinting at extensions to the known gold mineralisation and reinforcing rare earth element prospects.

PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.

Propel Funeral Partners has released its FY25 financial guidance projecting steady revenue growth despite temporary industry volume contraction, alongside announcing the upcoming retirement of its Managing Director and Co-Founder.

Strickland Metals reports robust diamond drilling results at its Gradina Prospect, extending high-grade gold mineralisation and setting the stage for a maiden resource estimate in late 2025.

Straker Ltd reports a solid FY25 performance marked by a strategic shift from legacy translation services to AI-powered language verification, underpinned by robust cash reserves and improved profitability.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited has announced an ordinary dividend of AUD 0.197 per share for the half-year ending March 2025, payable in July with flexible currency options for shareholders worldwide.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.